Glycominds, LLC of Simi Valley at MEDICA 2017 in Düsseldorf -- MEDICA Trade Fair

Glycominds, LLC

4685 Runway St., Ste J, 93063 Simi Valley
United States of America

Telephone +1 805 791-2094

This company is co-exhibitor of
Messe Düsseldorf North America

Hall map

MEDICA 2017 hall map (Hall 3): stand C16-8

Fairground map

MEDICA 2017 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.03  Auto-immune diseases
  •  Diagnostics / kits for the gastro enterology

Diagnostics / kits for the gastro enterology

Our products

Product category: Diagnostics / kits for the gastro enterology


Glycominds IBDX® panel is a series of CE MARK IVD kits that help physicians identify patients who have Crohn’s Disease and which of the patients are at higher risk for bowel damage and surgery. These patients can be candidates for “top down” therapy with biologics. IBDX® is the most validated and cost-effective serological panel to aid in the deferential diagnosis of IBD vs. non-IBD and for CD vs. UC, as well as for predicting the probability of Crohn's Disease progression. 
IBDX kits achieved CE MARK regulation. 
All kits are Quick and Easy to use with short incubation times and ready-to-use reagents. Also, all IBDX kits have break-a-well strips allowing high flexibility and economic use.
For additional information visit 

Improve Sensitivity and Specificity 
The IBDX biomarkers panel: gASCA, ALCA, ACCA, AMCA, Anti-L and Anti-C were analyzed on over 7,500 patients' samples in multiple independent clinical studies around the globe, including: Australia, Belgium, Canada, China, Czech Republic ,France, Germany, Greece, Hungry, Italy, Israel, Poland, Saudi Arabia and the U.S. – which makes it the most validated panel for IBD. 

Studies showed up to 97% specificity in differentiating CD from US patients and up to 70% sensitivity in identifying patients with UC.  It has been reported up to 85.5% sensitivity in identifying patients with CD using multiple markers and up to 56.4% sensitivity in identifying CD patients who are sero-negative to anti-Saccharomyces Cerevisiae antibody (ASCA). 

Crohn's Disease Progression
Three Crohn’s disease prognostic levels for disease severity are provided, allowing for improved treatment decisions.

       Patients positive for two or more IBDX Antibodies:
        - 70% are likely to have complicated disease
        - 60% are likely to require abdominal surgery

       Patients positive for three or more IBDX Antibodies:
         - 90% are likely to have complicated disease
         - 80% are likely to require abdominal surgery

Predict Disease Outcome
IBDX antibodies were shown to be able to predict patients who are at a higher risk for first complication and abdominal surgery (HR: 2.8 to 3.1, p<0.007).

Pediatric Value
Inflammatory Bowel Disease diagnosis and Crohn’s disease risk levels and prognostic information were validated prospectively in adults and children

More Less

About us

Company details

Glycominds International - the leading provider of digestive disease solutions

About Glycominds International
For more than 15 years, Glycominds has been a leading groundbreaker in microbiome biomarker research, offering the only validated serum biomarker tests on the market for Inflammatory Bowel Disease. Our laboratories produce results from a strong and proprietary technology platform, providing answers to physicians and allowing many patients to benefit from personalized control over their diagnosis and/or progression of their disease.

Glycominds international, an innovative diagnostics company, develops and commercializes gastrointestinal disease management tools and services. Our GI dry serum testing allow physicians to help identify patients who have Celiac Disease and Inflammatory Bowel Diseases (mainly Crohn’s Disease and Ulcerative Colitis) to achieve early, non-invasive, accurate and cost-effective diagnosis, predict Crohn’s Disease patients at a higher risk for more complicated disease, as well as monitoring Anti-TNF therapy.

More Less